HOOKIPA Pharma Inc - FORM 8 (OPD)

NEW YORK and VIENNA, Austria, Jan. 08, 2025 (GLOBE NEWSWIRE) --

FORM 8 (OPD)

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER
Rules 8.1 and 8.2 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

2.        POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

(b)      Rights to subscribe for new securities

3.      POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

Details of any interests, short positions and rights to subscribe (including directors’ and other employee options) of any person acting in concert with the party to the offer making the disclosure:

a) Interests held by the directors of HOOKIPA Pharma Inc., their close relatives and related trusts

*Rounded down to two decimal places.

(b) Interests held as options or awards under the share plans of HOOKIPA Pharma Inc. by the directors of HOOKIPA Pharma Inc. and their close relatives and related trusts who are not exempt principal traders for the purposes of Rule 8 of the Code

(1) The restricted stock units shall vest in two equal installments on July 22, 2025 and July 22, 2026, subject to the director’s continuous service through each such date.
(2) This option award shall vest and become fully exercisable on the earlier to occur of (a) June 17, 2025 and (b) the date of the Company’s next annual meeting of its stockholders.
(3) One-third of this option vested on June 9, 2024, with the remainder vesting in 8 equal quarterly installments thereafter.
(4) 25% of this option vested and became exercisable on April 17, 2020, with the remainder vesting in 8 equal quarterly installments thereafter.
(5) 25% of this option vested and became exercisable on October 1, 2019, with the remainder vesting in 12 equal quarterly installments thereafter.
(6) The shares subject to this option will vest in thirty-six equal monthly installments commencing July 22, 2024, subject to the director’s continuous service through each such date.

c) Interests and short positions held by investment managers, investment advisers and connected advisors of HOOKIPA Pharma Inc.

Not applicable.

(d) Interests held by other presumed concert parties of HOOKIPA Pharma Inc.

Not applicable.
  
(e) Rights to subscribe for new securities held by other presumed concert parties of HOOKIPA Pharma Inc.

Not applicable.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

(b)        Agreements, arrangements or understandings relating to options or derivatives

(c)        Attachments

Are any Supplemental Forms attached?

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.